Last reviewed · How we verify
DST-0509
DST-0509 is a small molecule that targets the SGLT2 receptor.
DST-0509 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | DST-0509 |
|---|---|
| Also known as | deferasirox tablets |
| Sponsor | DisperSol Technologies, LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, DST-0509 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. DST-0509's effects on blood glucose levels may also have cardiovascular benefits.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DST-0509 CI brief — competitive landscape report
- DST-0509 updates RSS · CI watch RSS
- DisperSol Technologies, LLC portfolio CI